The life-sciences industry cloud — agentic CRM, AI "labor" and a fortress balance sheet breaking out to new highs while tech sells off — Quick Take
Veeva is the #3 name by turnover on the Fri 16 Oct US VolumeSurge screen (+5.27% to $313.03 on ~2.9M shares / ~$897M turnover) and the largest ≥US$15B name on that screen that isn't already inside the 30-day coverage window — #1 Coinbase (21 Sep) and #2 Circle (27 Sep) are both recent, so the screener's own top-picks ladder hands us VEEV, and it sits in Healthcare, the #2 sector by count (13/50) behind only Technology (19/50). The company-specific trigger is an enterprise win, not a tape move: on 13 October IQVIA (NYSE: IQV) expanded its partnership and selected Veeva's clinical operations applications (CTMS and related) as its enterprise-standard tools, which drove analyst estimate revisions and a breakout to a fresh 52-week high on 15 Oct. That it happened while the wider tape was selling "AI anything" — CoreWeave CDS at distress levels on AI-debt worries, Nvidia/AMD/Dell sliding, memory names hammered on a 2029 oversupply scare — makes the relative strength notable: this is the AI *application* layer with recurring revenue and no capex arms race.
| Year (FY ends Jan) | Revenue | Rev Growth | Op Margin (GAAP) | Net Income |
|---|---|---|---|---|
| FY2022 (Jan '22) | $1,851M | +26.3% | 27.3% | $427M |
| FY2023 (Jan '23) | $2,155M | +16.4% | 21.3% | $488M |
| FY2024 (Jan '24) | $2,364M | +9.7% | 18.2% | $526M |
| FY2025 (Jan '25) | $2,747M | +16.2% | 25.4% | $714M |
| FY2026 (Jan '26) | $3,195M | +16.3% | 29.6% | $909M |
| TTM (Jul '26) | $3,458M | +16.5% | 29.9% | $1,015M |
Margin and profit have inflected hard off the FY2024 trough as the company moved past the Salesforce-platform transition and scaled its own Vault platform: GAAP operating margin went 18.2% → 25.4% → 29.6% across FY2024-FY2026, and TTM net income crossed $1B on a $3.46B revenue base. The most recent quarter (Q2 FY2027, ended 31 Jul 2026, reported 26 Aug) beat guidance on every metric: revenue $928.0M, +18% YoY (subscriptions $766.8M, +16%); GAAP operating income $275.0M (+40%); non-GAAP operating income $415.9M for a 44.8% non-GAAP operating margin; GAAP net income $273.4M (+37%) and non-GAAP EPS $2.35 vs $1.99. Management said its full-year view "improved across the board" and the FY2027 guide is ~$3.69B revenue with ~$9.21 non-GAAP EPS (~14% growth). Balance sheet is pristine: ~$7.1B net cash (~$42.6/share), Debt/Equity 0.02x, TTM free cash flow ~$1.64B (a ~47% FCF margin) with capex of only ~$27M a year. Vault CRM now has 180+ customers live including five top-20 biopharmas and 12 top-20 commitments globally; Veeva Falcon (an "agentic labor" platform for clinical, regulatory and safety) had five early adopters and is on track for initial go-lives this year.
This is the highest-quality large-cap on today's momentum screen and the cleanest way to own the "AI application layer" in life sciences: a debt-free, ~47%-FCF-margin compounder whose AI products ride on an installed, regulated base rather than a capex treadmill, which is exactly why it could make a new high while AI-infrastructure names sold off. The edge is durability, not cheapness — at ~32x forward earnings with the average price target below spot and RSI stretched, you are paying up for a business that grows mid-to-high teens and could re-rate further if Falcon and Vault CRM AI attach rates surprise at Q3 (19 Nov). The risk is that you are buying a fresh all-time high in a market where "beaten-down AI infrastructure" is the crowded value trade; a soft Q3 or any pharma-budget wobble and the multiple gives back fast. Interesting to own for the quality and the AI optionality — but only with eyes open on the setup and a plan for the post-earnings print.
Disclaimer: AI-generated quick take for informational purposes only. Not investment advice. Data from public filings and financial data providers (company IR, stockanalysis.com, GuruFocus, Motley Fool, Business Wire) as of the 15 Oct 2026 US close.